Cerus Endovascular and Balt this week announced a strategic distribution agreement to provide AB Medica with the exclusive rights to market and sell the Countour Neurovascular System and the Neqstent Coil Assisted Flow Diverter devices.
The distribution agreement is currently limited to Germany. The financial details of the deal were not disclosed.
“Our partnership with Balt, an internationally-recognized pioneer in the neurovascular sector, reflects the strength of our innovative product line and will provide significantly increased awareness and more rapid penetration of both the Contour Neurovascular System and the Neqstent device within Germany, the largest market within the European Union (EU),” president of Cerus Endovascular Stephen Griffin said in a news release. “Physicians in Germany have indicated their desire for greater access to our products and have, therefore, been very supportive of our decision to partner locally with AB Medica. We are excited to begin working closely together and eventually, to extending the distribution agreement into other key EU countries.”
The Contour Neurovascular System targets the neck of the aneurysm. It is designed to treat a range of aneurysm morphologies, including enraptured wide-necked bifurcation and bifurcation aneurysms.
Contour is designed to prove a combination of flow diversion at the neck of the aneurysm and flow disruption within the aneurysm sac.
“This partnership represents the achievement of an important milestone in our stated strategy for a controlled product roll-out in key international markets such as Germany,” chairperson of Cerus Endovascular Sam Milstein said.
“Balt has a long history of delivering innovative, life-saving devices to the hands of physicians. With this partnership with Cerus, we are happy to continue with this tradition and look forward to providing two new unique products to physicians in Germany,” Balt CEO Pascal Girin said.
